ChiCTR2600117446 版本V1.0 版本创建时间2026/01/23 17:13:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600117446 

最近更新日期:

Date of Last Refreshed on:

2026-01-23 17:13:47 

注册时间:

Date of Registration:

2026-01-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

日间腹腔镜胆囊切除术术中单次注射低剂量艾斯氯胺酮对术后恢复质量的影响:一项随机对照临床研究

Public title:

Effect of a Single Intraoperative Injection of Low-Dose Esketamine on Postoperative Recovery Quality in Ambulatory Laparoscopic Cholecystectomy: A Randomized Controlled Clinical Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

日间腹腔镜胆囊切除术术中单次注射低剂量艾斯氯胺酮对术后恢复质量的影响:一项随机对照临床研究

Scientific title:

Effect of a Single Intraoperative Injection of Low-Dose Esketamine on Postoperative Recovery Quality in Ambulatory Laparoscopic Cholecystectomy: A Randomized Controlled Clinical Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李欣龙 

研究负责人:

陈钢 

Applicant:

Li Xinlong  

Study leader:

Chen Gang  

申请注册联系人电话:

Applicant telephone:

+86 188 6810 8971

研究负责人电话:

Study leader's telephone:

+86 137 5711 8681

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

782507460@qq.com

研究负责人电子邮件:

Study leader's E-mail:

chengang120@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市庆春东路3号

研究负责人通讯地址:

浙江省杭州市庆春东路3号

Applicant address:

No. 3, Qingchun East Road, Hangzhou, Zhejiang Province

Study leader's address:

No. 3, Qingchun East Road, Hangzhou, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属邵逸夫医院

Applicant's institution:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

研究负责人所在单位:

浙江大学医学院附属邵逸夫医院

Affiliation of the Leader:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

邵逸夫医院伦审2026研第0094号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属邵逸夫医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-22 00:00:00

伦理委员会联系人:

许鸣

Contact Name of the ethic committee:

Xu Ming

伦理委员会联系地址:

浙江省杭州市庆春东路3号

Contact Address of the ethic committee:

No. 3, Qingchun East Road, Hangzhou, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8600 6811

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属邵逸夫医院

Primary sponsor:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市庆春东路3号

Primary sponsor's address:

No. 3, Qingchun East Road, Hangzhou, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属邵逸夫医院

具体地址:

浙江省杭州市庆春东路3号

Institution
hospital:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Address:

No. 3, Qingchun East Road, Hangzhou, Zhejiang Province

经费或物资来源:

自费

Source(s) of funding:

Self-funded

Target disease:

Laparoscopic Cholecystectomy

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较术中单次静脉注射低剂量艾斯氯胺酮对日间腹腔镜胆囊切除术患者术后恢复质量的影响。  

Objectives of Study:

To Compare the Effect of a Single Intraoperative Intravenous Injection of Low-Dose Esketamine on the Quality of Postoperative Recovery in Patients Undergoing Ambulatory Laparoscopic Cholecystectomy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄18-65周岁(包括边界值); 2. 拟择期行日间腹腔镜胆囊切除术的患者; 3. 美国麻醉医师协会(ASA)分级I-II级; 4. 能理解并独立完成 QoR-15问卷; 5. 自愿参加本研究,并且签署知情同意书。

Inclusion criteria

1. Age 18-65 years old (including the boundary values); 2. Patients scheduled for elective day-case laparoscopic cholecystectomy; 3. American Society of Anesthesiologists (ASA) classification I-II; 4. Able to understand and complete the QoR-15 questionnaire independently; 5. Voluntarily participating in this study and signing the informed consent form.

排除标准:

1. 因任何原因在手术前经历过疼痛的患者和服用镇痛药物的患者; 2. 严重心肺系统疾病(如失代偿性心力衰竭、重度慢性阻塞性肺疾病); 3. 对艾斯氯胺酮或相关麻醉药物过敏; 4. 有血压或颅内压升高严重风险的患者; 5. 控制不佳的或未经治疗的高血压患者; 6. 未经治疗或治疗不足的甲状腺功能亢进患者; 7. 严重肝、肾、神经系统或代谢性疾病; 8. 既往有精神疾病史或长期使用抗精神病药物; 9. 弱势群体,包括精神疾病者、认知损伤者、危重患者、孕妇、文盲等; 10. 存在研究者认为受试者不适合参加本研究的其他情况。

Exclusion criteria:

1. Patients who have experienced pain before surgery for any reason and those taking analgesics; 2. Severe cardiovascular or pulmonary diseases (such as decompensated heart failure, severe chronic obstructive pulmonary disease); 3. Allergic to esketamine or related anesthetics; 4. Patients with a high risk of hypertension or increased intracranial pressure; 5. Patients with poorly controlled or untreated hypertension; 6. Patients with untreated or inadequately treated hyperthyroidism; 7. Severe liver, kidney, neurological, or metabolic diseases; 8. History of psychiatric disorders or long-term use of antipsychotic drugs; 9. Vulnerable populations, including individuals with psychiatric disorders, cognitive impairments, critically ill patients, pregnant women, illiterate individuals, etc.; 10. Other conditions that the investigator believes make the subject unsuitable for participation in this study.

研究实施时间:

Study execute time:

From 2026-02-01 00:00:00 To 2026-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-01 00:00:00 To 2026-07-01 00:00:00  

干预措施:

Interventions:

组别:

艾斯氯胺酮组

样本量:

50

Group:

Esketamine Group

Sample size:

干预措施:

切皮之前3分钟,静脉注射艾斯氯胺酮(0.25mg/kg)

干预措施代码:

Intervention:

Intravenous injection of esketamine (0.25 mg/kg) was administered 3 minutes prior to skin incision

Intervention code:

组别:

对照组

样本量:

50

Group:

Control Group

Sample size:

干预措施:

切皮之前3分钟,静脉注射等量生理盐水

干预措施代码:

Intervention:

An equivalent volume of normal saline was intravenously administered 3 minutes prior to skin incision

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江  

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

浙江大学医学院附属邵逸夫医院 

单位级别:

三甲  

Institution
hospital:

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后第1天QoR-15总评分

指标类型:

主要指标

Outcome:

Total QoR-15 Score on the First Postoperative Day

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前QoR-15总评分

指标类型:

次要指标

Outcome:

Total preoperative QoR-15 score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后第1天QoR-15各维度评分

指标类型:

次要指标

Outcome:

Dimension-specific QoR-15 scores on the first postoperative day

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PACU、术后6h和出院时静息及活动状态下的 VAS 疼痛评分

指标类型:

次要指标

Outcome:

Visual Analogue Scale (VAS) pain scores at rest and during movement in the Post-Anesthesia Care Unit (PACU), at 6 hours postoperatively, and at discharge

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉前、气管插管后5min、拔除气管导管后5min、出PACU时、出院时的血压及心率

指标类型:

次要指标

Outcome:

Blood pressure and heart rate before anesthesia, at 5 minutes after tracheal intubation, at 5 minutes after tracheal extubation, upon discharge from PACU, and at hospital discharge

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

在PACU时的麻醉后恢复评分(PAR评分)

指标类型:

次要指标

Outcome:

Post-Anesthesia Recovery (PAR) score in the PACU

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PACU滞留时间

指标类型:

次要指标

Outcome:

PACU length of stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次下床活动时间(h)

指标类型:

次要指标

Outcome:

Time to first postoperative ambulation (h)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件如恶心、呕吐、肩膀痛、肌肉酸痛以及头晕幻觉等精神症状

指标类型:

次要指标

Outcome:

Adverse events, including nausea, vomiting, shoulder pain, myalgia, and psychiatric symptoms such as dizziness and hallucinations

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日间临床路径完成率

指标类型:

次要指标

Outcome:

Day-case clinical pathway completion rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用在线随机化系统进行随机分组(按照1:1的比例),随机序列由计算机生成

Randomization Procedure (please state who generates the random number sequence and by what method):

Participants were randomly assigned in a 1:1 ratio using an online randomization system. The random sequence was generated by a computer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者及麻醉实施医生设盲

Blinding:

Blinding for subjects and anesthesiologists

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-23 17:13:47